Edimer Pharmaceuticals

Edimer Pharmaceuticals: Committed to improving the health and quality of life for XLHED families. Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked hypohidrotic ectodermal dysplasia (XLHED). XLHED is a rare orphan disease that can cause a range of symptoms, including insufficient sweat glands, poor temperature regulation, respiratory issues, and abnormalities in hair and teeth. Edimer is led by a group of seasoned veterans from the biotechnology industry with extensive experience in drug development, supported by a robust network of world-class clinical and scientific advisors.